TY - JOUR
T1 - Comparison of DNA and mRNA vaccines against cancer
AU - Jahanafrooz, Zohreh
AU - Baradaran, Behzad
AU - Mosafer, Jafar
AU - Hashemzaei, Mahmoud
AU - Rezaei, Tayebeh
AU - Mokhtarzadeh, Ahad
AU - Hamblin, Michael R.
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2020/3
Y1 - 2020/3
N2 - Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.
AB - Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.
UR - http://www.scopus.com/inward/record.url?scp=85076847116&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2019.12.003
DO - 10.1016/j.drudis.2019.12.003
M3 - Review article
C2 - 31843577
AN - SCOPUS:85076847116
SN - 1359-6446
VL - 25
SP - 552
EP - 560
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 3
ER -